The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Robin Park
No Relationships to Disclose
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Anup Kasi
Honoraria - OncLive
Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals
 
Azhar Saeed
No Relationships to Disclose
 
Elizabeth Ng
No Relationships to Disclose
 
Kayra Thompson
No Relationships to Disclose
 
Stephanie Moya
No Relationships to Disclose
 
Lori Barbosa
No Relationships to Disclose
 
Milind Phadnis
No Relationships to Disclose
 
Stephen K. Williamson
Stock and Other Ownership Interests - Horizon Therapeutics; Iovance Biotherapeutics; Merus
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst)
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Forty Seven; Hylapharm; Moderna Therapeutics; MorphoSys; Zymeworks
Research Funding - Astellas Pharma; Exelixis; Incyte; Lilly; Nektar; Pfizer; Regeneron; Sanofi; Tolero Pharmaceuticals; Xencor
 
Weijing Sun
Research Funding - Merck (Inst)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Archer; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Natera; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Seagen; Taiho Pharmaceutical; Tempus; Zymeworks
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech/Roche; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Genentech; Guardant Health; Lilly; Merck; Tempus